On the other hand, the use of PDIA3 inhibitors, such as punicalagin [87], in the late phase of AD, might reduce the PDIA3-dependent pro-apoptotic effects and thus slow down the disease progression. The gene discussed is PDIA3; the disease is Alzheimer disease.